GERN
Geron Corp
NASDAQ · Biotechnology
$1.53
+0.07 (+4.79%)
Open$1.48
Previous Close$1.46
Day High$1.57
Day Low$1.46
52W High$3.03
52W Low$1.04
Volume—
Avg Volume14.62M
Market Cap976.68M
P/E Ratio—
EPS$-0.12
SectorBiotechnology
Analyst Ratings
Buy
13 analysts
Price Target
+1,142.5% upside
Current
$1.53
$1.53
Target
$19.01
$19.01
$12.94
$19.01 avg
$24.33
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 76.09M | 153.95M | 141.15M |
| Net Income | -172,483,588 | -36,660,557 | -32,364,939 |
| Profit Margin | -226.7% | -23.8% | -22.9% |
| EBITDA | -173,058,107 | -44,322,691 | -40,350,825 |
| Free Cash Flow | — | -25,979,960 | -28,291,864 |
| Rev Growth | +281.2% | +15.1% | +6.9% |
| Debt/Equity | 0.87 | 0.42 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |